ATXI: Avenue Therapeutics, Inc. Stock

by  •  • Comments Off on ATXI: Avenue Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.48
Enterprise Value ($M) -1.65
Book Value ($M) 1.90
Book Value / Share 2.02
Price / Book 1.31
NCAV ($M) 1.90
NCAV / Share 2.02
Price / NCAV 1.31

Profitability (mra)
Return on Invested Capital (ROIC) -3.78
Return on Assets (ROA) -4.31
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 2.34
Current Ratio 2.34

Balance Sheet (mrq) ($M)
Current Assets 3.31
Assets 3.31
Liabilities 1.41
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -14.54
Net Income -10.38
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -9.45
Cash from Investing -3.00
Cash from Financing 7.53

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-02 13G/A Davidow Robert L 2.90 -98.69
04-17 13D/A Fortress Biotech, Inc. 8.00 239.74
01-02 13G/A Sabby Management, Llc 4.99 150.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 32,095 115,079 27.89
2024-07-25 203,665 693,198 29.38
2024-07-24 8,064 67,865 11.88
2024-07-23 42,923 115,215 37.25
2024-07-22 1,292 11,930 10.83

(click for more detail)

Similar Companies
ASRT – Assertio Holdings, Inc. ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc. ATYR – aTyr Pharma, Inc.
AVTX – Avalo Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io